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Asthma is a serious health and socioeconomic issue all over the world, affecting more than
300 million individuals.The disease is considered as an inﬂammatory disease in the airway,
leading to airway hyperresponsiveness, obstruction, mucus hyper-production and airway
wall remodeling.The presence of airway inﬂammation in asthmatic patients has been found
in the nineteenth century. As the information in patients with asthma increase, paradigm
change in immunology and molecular biology have resulted in an extensive evaluation of
inﬂammatory cells and mediators involved in the pathophysiology of asthma. Moreover,
it is recognized that airway remodeling into detail, characterized by thickening of the
airway wall, can be profound consequences on the mechanics of airway narrowing and
contribute to the chronic progression of the disease. Epithelial to mesenchymal transition
plays an important role in airway remodeling.These epithelial and mesenchymal cells cause
persistence of the inﬂammatory inﬁltration and induce histological changes in the airway
wall, increasing thickness of the basement membrane, collagen deposition and smooth
muscle hypertrophy and hyperplasia. Resulting of airway inﬂammation, airway remodeling
leads to the airway wall thickening and induces increased airway smooth muscle mass,
which generate asthmatic symptoms. Asthma is classically recognized as the typical Th2
disease, with increased IgE levels and eosinophilic inﬂammation in the airway. Emerging
Th2 cytokines modulates the airway inﬂammation, which induces airway remodeling.
Biological agents, which have speciﬁc molecular targets for these Th2 cytokines, are
available and clinical trials for asthma are ongoing. However, the relatively simple paradigm
has been doubted because of the realization that strategies designed to suppress Th2
function are not effective enough for all patients in the clinical trials. In the future, it is
required to understand more details for phenotypes of asthma.
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INTRODUCTION
Asthma is characterized by the action of airway leading to
reversible airﬂow obstruction in association with airway hyper-
responsiveness (AHR) and airway inﬂammation (Holgate, 2012).
The disease is affecting more than 300 million persons all over the
world, with approximately 250,000 annual deaths (Bousquet et al.,
2007). In the last couple of decades, as the inhaled corticosteroid
has become the major treatment agent for asthma, the mortality of
asthmahas decreased (Wijesinghe et al., 2009). Meanwhile, allergic
diseases, such as asthma, have markedly increased in the past half
centuries associated with urbanization (Alfvén et al., 2006). Chil-
dren have the greatest percentage of asthma compared with other
generation groups (Centers for Disease Control and Prevention,
2011). Then, it is expected that the number of the patients will
increase by more than 100 million by 2025 (Masoli et al., 2004).
Generally, most asthma starts from childhood in relation to
sensitization to common inhaled allergens, such as house dust
mites, cockroaches, animal dander, fungi, and pollens. These
inhaled allergens stimulate T helper type 2 (Th2) cell prolifer-
ation, subsequently Th2 cytokines, interleukin (IL)-4, IL-5 and
IL-13 production and release. Many basic and clinical stud-
ies suggested that airway inﬂammation was a central key to
the disease pathophysiology. The existence of chronic airway
inﬂammation in asthma has been recognized for over a century.
The inﬂammation is induced by the release of potent chemical
mediators from inﬂammatory cells. Resulted of chronic airway
inﬂammation, airway remodeling, characterized by thickening of
all compartments of the airway wall, is occurred and may have
profound consequences on the mechanics of airway narrowing in
asthma and contribute to the chronicity and progression of the
disease.
As allergic sensitization, allergen can be taken up by dendritic
cells (DCs), which process antigenic molecules and present them
to naïve T helper cells. Consequently the activation of allergen-
speciﬁc Th2 cells is occurred, the cells play an important role in
developing the asthma. Nowadays, it is known that Th17 cells and
Th9 cells also modulate the disease. Th17 cells produce IL-17A,
IL-17F, and IL-22. These cytokines induce airway inﬂammation
and IL-17A enhance smooth muscle contractility.
Allergic diseases are caused by inappropriate immunological
responses to allergens without pathogenesis driven by a Th2-
mediated immune response. The hygiene hypothesis has been
used to explain the increase in allergic diseases since industri-
alization and urbanization, and the higher incidence of allergic
diseases in more developed countries. The hypothesis has now
expanded to include exposure to symbiotic bacteria and parasites
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as important modulators of immune system development, along
with infectious agents (Grammatikos, 2008). Recently, asthma has
not been recognized as a simple Th2 disease, which is charac-
terized by IgE elevation and relatively eosinophilia. Th17 and
Th9 cell subtype are known to contribute the inﬂammation
or enhancing smooth muscle contraction or stimulating mast
cells.
HISTOPATHOLOGY OF ASTHMATIC AIRWAY
Asthma is considered in terms of its hallmarks of reversible airﬂow
obstruction, non-speciﬁc bronchial hyperreactivity and chronic
airway inﬂammation (American Thoracic Society, 1987). Osler
(1892) mentioned in the classic textbook, the inﬂammatory pro-
cess, affecting the conducting airways with relative sparing of
the lung parenchyma. Huber and Koesser (1922) provided a
comprehensive perspective of the histopathological features of
asthma. That is, the lungs are usually hyperinﬂated as a conse-
quence of extensive mucous plugging in segmental, subsegmental
bronchus and peripheral airways, but the lung parenchyma in
general, remains relatively intact in subjects who die in exacer-
bation, so-called status asthmatics. The composition of mucous
includes cellular debris from necrotic airway epithelial cells, an
inﬂammatory cells including lymphocytes, eosinophils, and neu-
trophils, plasma protein exudate, and mucin that is produced by
goblet cells (Unger, 1945; Bullen, 1952; Dunnill, 1960; Messer
et al., 1960). The airway epithelium typically shows sloughing of
ciliated columnar cells, with goblet cell and squamous cell meta-
plasia as a sign of airway epithelial repair. There is increased
thickness of the subepithelial basementmembrane, however, some
studies have established that the true basal lamina is of normal
thickness, and the apparent increase in thickness is related to accu-
mulation of other extracellular matrix components beneath the
basal lamina (Roche et al., 1989). The asthmatic airway showed
a thickness with inﬂammatory cell inﬁltration consisting of an
admixture of T lymphocytes and eosinophils, mast cells (Car-
roll et al., 1997; Hamid et al., 1997). Interestingly, prominent
neutrophil inﬁltrates have been reported to be a speciﬁc feature
of the clinical entity of sudden onset fatal asthma (Sur et al.,
1993).
Nowadays investigators can easily obtain lung tissue and bron-
choalveolar lavage (BAL) specimens from the patients with asthma
(Salvato, 1968; Djukanovic et al., 1991). Results of studies of BAL
(Robinson et al., 1992) and lung tissue specimens (Minshall et al.,
1998) have strongly implicated a role for cytokines produced by
the Th2 subset of CD4+ T cells in the pathogenesis of asthma.
For example, IL-13 plays an important role in regulating the air-
way inﬂammation in asthma (Wills-Karp et al., 1998; Zhu et al.,
1999).
In recent years, there has been increasing interest in the mecha-
nism of airway wall remodeling in asthma, owing to the increasing
realization that airway inﬂammation alone is not enough to
explain the chronicity or progression of asthma (Holgate et al.,
1999). The nature of airway remodeling may be considered in
terms of extracellular matrix deposition. It is postulated that
the injured airway epithelium acts as a continuous stimulus
for airway remodeling (Holgate et al., 1999), and this is sup-
ported by results of recent cell culture experiments examining
interactions of bronchial epithelial cells with myoﬁbroblasts in
response to injurious stimuli (Zhang et al., 1999). The remod-
eling is predicted to have little effect on baseline respiratory
mechanics, the physiological effects of extracellular matrix accu-
mulation are predicted to result in an exaggerated degree of
narrowing for a given amount of airway smooth muscle (ASM)
contraction.
Airway wall thickening is greater in the asthmatic patients than
normal subjects, and severe patients have greater (Awadh et al.,
1998). This thickness is due to an increase in ASM mass and
mucous glands (Johns et al., 2000). The airﬂow limitation is also
compounded by the presence of increased mucous secretion and
inﬂammatory exudate (Chiappara et al., 2001). Thus, the results
from many studies have supported that airway remodeling related
to airway inﬂammation. Surprisingly, physical force generated
by ASM in bronchoconstriction without additional inﬂammation
induces airway remodeling in patients with asthma (Grainge et al.,
2011). Despite these recent advances, further work is necessary to
establish a causal relationship between airway remodeling and the
severity of asthma (Bento and Hershenson, 1998).
AIRWAY EPITHELIUM
The structural changes in the asthmatic airway result from inter-
dependent inﬂammatory and remodeling processes (Chiappara
et al., 2001). In the processes, inﬂammation occurs common fea-
tures, vascular congestion, exudaution, and inﬂammatory cell
recruitment to the interstitial tissue. Furthermoremucus secretion
and desquamation of epithelial cells are increased. The chronic
inﬂammatory changes develop epithelium-mesenchymal interac-
tions (Holgate et al., 2000). The number of myoﬁbroblasts, which
deposit collagens, increases in the understructure of epithelium,
the proximity of the smooth muscle layer and the lamina reticu-
laris in the patients. Subepithelial collagens cause thickening and
increasing density of the basement membrane.
The airway inﬂammation gives damage to the epithelium and
damaged epithelial cells will be repaired in the injury-repair cycle.
Some studies showed that epithelial cells of untreated asthmatic
patients had low level expression of proliferating markers, despite
extensive damage, revealing a potential failure in the epithelial
injury-repair cycle in response to local inﬂammation and inhaled
agents (Bousquet et al., 2000). Injury to the epithelium results
in a localized and persistent increase in epidermal growth factor
(EGF) receptor, a mechanism that may cause the epithelium to be
locked in a repair phenotype (Puddicombe et al., 2000). Epithelial
cells which are in repair phase produced some proﬁbrotic media-
tors, including transforming growth factor-β (TGF-β), ﬁbroblast
growth factor and endothelin, which regulate ﬁbroblast and
myoﬁbroblast to release collagen, elastic ﬁber, proteoglycan, and
glycoprotein and these substances induce airway wall thickening
(Holgate et al., 2000). Myoﬁbroblast is a rich source of collagen
types I, II, and V, ﬁbronectin and tenascin that also accumulate in
the airway wall and induce thickening lamina reticularis (Roche
et al., 1989; Brewster et al., 1990). This processmay contribute phe-
nomena by augmentation of airway narrowing because the inner
airway wall volume increases.
Eosinophils seem to contribute to airway remodeling in sev-
eral ways, including through release of eosinophil-derived TGF-β,
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cationic proteins, and cytokines, as well as through interactions
withmast cell and epithelial cells. Manyof these factors candirectly
activate epithelium and mesenchymal cells, deeply related to the
development of airway remodeling (Kariyawasam and Robinson,
2007; Aceves and Broide, 2008; Venge, 2010). Eosinophil-derived
cytokines are in the modulation of Th2 responses that trigger
macrophage production of TGF-β1, which serves as a stimulus for
extracellular matrix production (Fanta et al., 1999; Holgate, 2001).
TGF-β1 induced epithelial to mesenchymal transition (EMT) in
alveolar epithelial cells and could contribute to enhance ﬁbrosis
in idiopathic lung ﬁbrosis (Wilson and Wynn, 2009). TGF-β1
might also contribute to enhance airway remodeling through
EMT. Indeed, anti-TGF-β1 treatment inhibits EMT in airway
epithelial cells (Yasukawa et al., 2013).
Airway epithelium is a barrier in the frontline against stimuli
from the environment, but in asthmatic epithelium is defective
in barrier function with incomplete formation of tight junctions,
that prevent allergen from penetrating into the airway tissue (Xiao
et al., 2011). The defect would induce that a proportion of the
asthma-related had biological properties to inﬁltrate the epithelial
barrier and trigger a danger signal to DCs. Components of house
dust mite, cockroach, animal, and fungal can disrupt epithelial
tight junctions and activate protease-activated receptors (Jacquet,
2011). The defective epithelial barrier function has also been
described in the pathophysiology of other allergic disease. There-
fore, healthy barrier function is important to avoid sensitization
and development in allergic disease.
AIRWAY SMOOTH MUSCLE
Abnormalities of asthmatic ASM structure and morphology have
been described by Huber and Koesser (1922) in the ﬁrst quarter of
twentieth century when they reported that smooth muscle from
the patients who died by acute exacerbation was increase much
greater than in those who died from another disease. Airﬂow lim-
itation mainly due to reversible smooth muscle contraction is a
most important symptom of the disease. Therefore, ASM plays a
material role in asthma. Abnormal accumulation of smooth mus-
cle cells is another mechanism of airway remodeling. Some in
vivo animal studies conﬁrmed that prolonged allergen exposure
increase smooth muscle thickness in the airway (Salmon et al.,
1999). It is still unknown whether the phenomenon is occurred
by fundamental changes in the phenotype of the smooth muscle
cells, is caused by structural or mechanical changes in the non-
contractile elements of the airway wall. There are two different
ways by which cyclic generation of length and force could inﬂu-
enceASMcontracting and airwaynarrowing. Theprocesses,which
are myosin binding and plasticity, have different biochemical and
physical mechanisms and consequences. They have the potential
to interact and to have a fundamental effect on the contractual
capacity of smooth muscle and its potential to cause excessive
airway narrowing (King et al., 1999).
Like other muscles, ASM is also provoked to contract with
intracellular calcium ions (Ca2+), which comes from the extra-
cellular environment through voltage-dependent calcium channel
or from the sarcoplasmic reticulum stores (Figure 1). The source
FIGURE 1 | Regulation of ASM contractility. ASM contraction is
induced by calcium, regulated two different pathways. First, ASM is
evoked by intracellular calcium inﬂux from SR depending on GPCR
stimulation or from the extracellular environment through voltage-
dependent calcium channel. Second, smooth muscle can be induced
calcium sensitivity by RhoA/Rho kinase pathway. RhoA activates
Rho-kinase which phosphorylates MLCP. pMLC phosphatase fails
to dephosphorylate MLC. KCl, potassium chloride; Ach, acetylcholine;
5-HT, 5-hydroxytryptamine (serotonin); PIP, phosphatidylinositol 4-phos-
phate; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP5K, 1-phos-
phatidylinositol-4-phosphate 5-kinase; DG, diacylglycerol; IP3, inositol
1,4,5-trisphosphate.
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of Ca2+ surge in ASM is mainly from intracellular sarcoplasmic
reticulum stores rather than from the extracellular Ca2+ seen in
cardiac, skeletal, and vascular muscle cells. Ligands to G-ptotein
coupled receptor (GPCR), such as acetylcholine andmethacholine,
induce the activation of phospholipase C (PLC), which in turn
leads to the formation of the inositol triphosphate (IP3; Chen et al.,
2012). Then, IP3 occurs to release Ca2+ from sarcoplasmic retic-
ulum (SR) stores, then Ca2+ forms a calcium-calmodulin comlex,
activates MLC kinase (MLCK) which phosphorylates regulatory
MLCs (rMLCs) forming phosphorylated-MLC (p-MLC; Berridge,
2009). Finally, this mechanism occurs to the activation of actin
and myosin crossbridges resulting in shortening and contraction
(Gunst and Tang, 2000).
And the contraction is also regulated by calcium sensitivity of
myosin light chain (MLC; Kudo et al., 2012). The p-MLC is regu-
lated byMLCphosphatase (MLCP)which converts p-MLCback to
inactiveMLC.MLCP is negatively controlled by Ras homolog gene
family, member A (RhoA) and its target Rho Kinase such as Rho-
associated, coiled-coil containing protein kinase (ROCK) which
phosphorylates myosin phosphatase target subunit 1 (MYPT-1).
Upregulation of the RhoA/Rho kinase signaling pathway inducing
to inhibition of MLCP would result in increased levels of p-MLC
and subsequently increased ASM contraction force. Increased
levels of RhoA protein and mRNA were found in airway hyperre-
sponsive animal models and this is probably medicated through
inﬂammatory cytokines, such as IL-13 and IL-17A that themselves
directly enhance the contractility of ASM (Chiba et al., 2009; Kudo
et al., 2012). For IL-17A, sensitized mouse conditional lacking
integrin αvβ8 on DCs shows attenuated reactivity against IL-17A-
induce antigen challenge. This is induced by that IL-17A itself
enhances the contractile force of ASM, through RhoA/Rho kinase
signaling change.
Airway smoothmuscle cells also contribute to the inﬂammatory
mechanisms and airway remodeling of asthma. The proactivating
signals, including viruses and immunoglobulin E could con-
vert ASM cells into a proliferative and secretory cell in asthma.
Naureckas et al. (1999) demonstrated the presence of smoothmus-
cle mitogens in the BAL ﬂuids from asthmatic individuals who
underwent allergen challenge. Smooth muscle proliferation is also
caused by the production of matrix metalloproteinase (MMP)-2,
which has been demonstrated to be an important autocrine fac-
tor that is required for proliferation (Johnson and Knox, 1999).
Production of MMP-2 from smooth muscle cells suggests that
ASM contributes to the extracellular matrix turnover and airway
remodeling. These cells may also participate in chronic airway
inﬂammation by interacting with both Th1- and Th2-derived
cytokines to modulate chemoattractant activity for eosinophils,
activated T lymphocytes, and monocytes/macrophages (Teran
et al., 1999).
In addition, recent studies demonstrated that eosinophils can
also contribute to airway remodeling during an asthma by enhanc-
ing ASM cell proliferation. Halwani et al. (2013) veriﬁed that
preventing eosinophil contact with ASM cells using speciﬁc anti-
bodies or blocking cysteinyl leukotrienes derived from eosinophils
was associated with inhibition of ASM proliferation. Moreover,
ASM-synthesized cytokines seem to direct the eosinophil dif-
ferentiation and maturation from progenitor cells, which can
promote perpetuation of eosinophilic inﬂammation and conse-
quently the tissue remodeling in asthma (Fanat et al., 2009). It
was also reported that TGF-β alone induces only weak mitogenic
effect onASMcells, however, it synergistically stimulatesASMpro-
liferation with methacholine which is agonist for the muscarinic
receptor (Oenema et al., 2013). These smooth muscle cell prolif-
erations related to airway remodeling can be the target to treat
asthma.
EPITHELIAL TO MESENCHYMAL TRANSITION ON ASTHMA
As airway remodeling on asthma attracts investigators interested
in airway remodeling on asthma, EMTs are recognized to be more
important in asthma than before. EMTs are biological processes
that epithelial cells lose their polarity and cell adhesion resulted in
fragility of tight junction and gain migratory and invasive prop-
erties to change their cell formation to mesenchymal cells (Kalluri
and Neilson, 2003). It is essential for processes including meso-
derm formation and neural tube formation in the development
and recently has also been reported to involve in wound healing,
in organ ﬁbrosis and in cancer metastasis. First, EMTs were found
in the embryogenesis. Epithelial cells are different from mesenchy-
mal cells in their phenotype. Epithelial cells connect each other,
forming tight junction. These cells have polarity in cytoskeleton
and bound to basal lamina. For mesenchymal cells, the polarity
is lost and shaped in spindle. Lately, EMTs are divided into three
subtypes, developmental (Type I), ﬁbrosis, tissue regeneration and
wound healing (Type II), and cancer progression and metastasis
(Type III; Kalluri and Weinberg, 2009).
Type II EMT involves in wound healing, resulted that it
contributes airway remodeling in asthma after airway epithelial
injury induced by inﬂammation. Type II EMT indicates that
epithelial tissue can be expressed plasticity (Thiery and Sleeman,
2006). It is initiated by extracellular signals, such as connection
with extracellular matrix; collagen or hyaluronic acids and by
growth factors; TGF-β and EGF. Among those signals, TGF-β
is established how it plays important role in airway remodel-
ing and EMT (Phipps et al., 2004; Boxall et al., 2006; Hackett
et al., 2009). TGF-β induces the expression of α-smooth mus-
cle actin and vimentin and the downregulation of E-cadherin
expression, inducing the dissolution of polarity of the epithelial
cell and intercellular adhesion. The such physiological effects of
TGF-β signaling in the system have been shown to depend on
microenvironment. Bone morphogenesis protein (BMP)-7 fails
to attenuate TGF-β-induced EMT, however, one of the family
member BMP-4 plays the role of EMT in the airway (Molloy
et al., 2008; Hackett et al., 2009). This TGF-β-induced attenua-
tion of intercellular adhesion and wound repair in EMT can be
enhanced by the proinﬂammatory cytokines tumor necrosis factor
(TNF)-α (Camara and Jarai, 2010). Furthermore, it was showed
that house dust mite, through EGF receptor enhanced TGF-β-
induce downregulation of E-cadherin in the bronchial epithelial
cells (Heijink et al., 2010). And house dust mite and TGF-β syn-
ergistically induced expression of mesenchymal markers vimentin
and ﬁbronectin. In chronic house dust mite-exposure model, the
airway epithelial cells were shown to elevate TGF-β expression
and nuclear phosphorylated Smad3. And in these cells, the tight-
junction proteinwas dissolved, occluding and expressedα-smooth
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muscle actin and collagen (Johnson et al., 2011). Inhaled aller-
gens might modify EMT, cooperating with cytokines which also
promote asthma.
MAST CELLS AND EOSINOPHILS
Mact cells can induce the activation of mesenchymal cells (Hol-
gate, 2000). The serine protease, tryptase which is released from
degranulating mast cells is a potent stimulant of ﬁbroblast and
smooth muscle cell proliferation, and is capable of stimulating
synthesis of type I collagen by human ﬁbroblasts. A major mecha-
nism involved in the regulation of ﬁbroblast proliferation appears
to be cleavage and activation of protease activated receptor-2 on
ﬁbroblasts (Akers et al., 2000). Mast cells may also inﬂuence the
development of airway remodeling in asthma by releasing large
amounts of plasminogen activator inhibitor type1. Moreover, Sug-
imoto et al. (2012) have shown that other mast cell proteases
regulate airway hyperreactivity. Mice lacking αvβ6 integrin are
protected from exaggerated airway narrowing. Mast cell pro-
teases are differentially expressed, in mouse mast cell protease 1
(mMCP-1) induced by allergen challenge in wild-type (WT) mice
and mMCP-4 increased at baseline in β6-deﬁcient mice. MCPs
from intraepithelialmast cell and their proteolytic substrates could
be regulate airway hyperreactivity.
Eosinophils are circulating granulocytes and at relatively low
levels in the bloodstream, upto 3% of white blood cells. These are
the major cell types that can be recruited to sites of inﬂamma-
tory responses (Huang et al., 2009; Isobe et al., 2012; Uhm et al.,
2012). The function of eosinophils in asthma is related to their
release of toxic granule proteins, reactive oxygen species (ROS),
cytokines, and lipid mediators (Liu et al., 2006). The recruit of
eosinophils into the epithelium and eosinophilic inﬂammation
is involved in the pathogenesis of asthma. The proinﬂamma-
tory mediators derived by eosinophil are major contributors to
inﬂammation in asthma, including airway epithelial cell dam-
age and desquamation, airway dysfunction of cholinergic nerve
receptors, AHR, mucus hypersecretion, and airway remodeling,
characterized by ﬁbrosis and collagen deposition (Kay, 2005; Watt
et al., 2005; Kanda et al., 2009; Walsh, 2010). Eosinophils are likely
to contribute to airway remodeling with release of eosinophil-
derived mediators such as TGF-β, secretion of cationic proteins,
and cytokines, as well as having interactions with mast cell and
epithelial cells. Those factors can directly activate epithelium and
mesenchymal cells (Venge, 2010). Moreover, recent data demon-
strated that eosinophils can also contribute to airway remodeling
with ASM cell proliferation.
EXTRACELLULAR MATRIX
The airways of asthmatic patients showed excess accumulation
of extracellular matrix components, particularly collagen, in the
subepithelial connective tissue and adventitia of the airway wall
(Kuwano et al., 1993; Gillis and Lutchen, 1999). The cellular inter-
actions in mast cells and ﬁbroblasts through protease activated
receptor-2 may contribute an abnormal mesenchymal cell prolif-
eration, and may account for the increased number of ﬁbroblasts
and myoﬁbroblasts that are found in the airways of asthmatic
subjects. Fibroblasts retain the capacity for growth and regen-
eration, and may evolve into various cell types, including smooth
muscle cells that subsequently becomemyoﬁbroblasts. Myoﬁbrob-
lasts can contribute to tissue remodeling by releasing extracellular
matrix components such as elastin, ﬁbronectin and laminin (Vig-
nola et al., 2000). It was seen that the numbers of myoﬁbroblasts
in the airway of asthmatic subjects increased and their num-
ber appeared to correlate with the size of the basement reticular
membrane (Holgate et al., 2000). Smooth muscle cells also have
the potential to alter the composition of the extracellular matrix
environment. The reticular basement membrane thickening is a
characteristic typical feature of the asthmatic airways. It appears
to consist of a plexiform deposition of immunoglobulins, collagen
types I and III, tenascin and ﬁbronectin (Jeffery et al., 2000), but
not of laminin.
Remodeling processes of the extracellularmatrix are less known
than the thickening of the lamina reticularis. Most asthmatic sub-
jects present with an abnormal superﬁcial elastic ﬁber network,
with fragmented ﬁbers (Bousquet et al., 2000). In the deeper layer
of elastic ﬁbers is also abnormal, the ﬁbers often being often patchy,
tangled, and thickened. Some studies using transmission electron
microscopy have shown that an elastolytic process occurs in asth-
matic patients, and in some patients disruption of ﬁbers has been
observed. In the case of fatal asthma, fragmentation of elastic
ﬁber has also been found in central airways, and was associated
with marked elastolysis (Mauad et al., 1999). These bundles are
seen to be hypertrophied as a result of an increased amount of
collagen and myoﬁbroblast matrix deposition occurring during
exaggerated elastic ﬁber deposition (Carroll et al., 1997). Loss of
lung elastic recoil force has been shown in adults with persistent
asthma and irreversible expiratory airﬂow obstruction. Persistent
asthmatic patients have severe abnormal ﬂow-volume curves in
expiration at both high and low lung volumes, and hyperinﬂa-
tion can be seen by residual volume, at forced residual capacity
and total lung capacity (Gelb and Zamel, 2000). The increased
elastolysis is part of a more complex process that regulates the
size of a submucosal network formed by elastic ﬁbers dispersed
in a collagen and myoﬁbroblast matrix (Chiappara et al., 2001).
These features induce changes in airway, as demonstrated by air-
way compliance, particularly in those patients who are suffering
from asthma for long period, supporting the concept that chronic
inﬂammation and remodeling of the airway wall may result in
stiffer dynamic elastic properties of the asthmatic airway (Brackel
et al., 2000). Furthermore, disruption of elastic ﬁbers may con-
tribute to a reduction in the preload and afterload for smooth
muscle contraction. Though it is difﬁcult to associate aspects of
remodeling with disease severity or degree of airways obstruction
and hyperresponsiveness (Mauad et al., 2007), some investigators
indicated that smooth muscle remodeling is related to the severity
of asthma (James et al., 2009). It has shown that the clinical expres-
sion of asthma (Brightling et al., 2002),AHR (Siddiqui et al., 2008)
and impaired airway relaxation (Slats et al., 2007) are associated
with mast cell counts in the ASM layer in asthma. The deposition
of extracellular matrix inside and outside the smooth muscle layer
in asthma also seems to be related to its clinical severity and is
altered as compared to healthy controls (Araujo et al., 2008; Kla-
gas et al., 2009). Yick et al. (2012) have shown that extracellular
matrix in ASM was related to the dynamics of airway function in
asthma.
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IMMUNE RESPONSE
ALLERGIC SENSITIZATION
Regarding to the immune system against allergy, it seems that
hygiene hypothesis would provide the reason why the number of
the patients with asthma is increasing, in relation with urban-
ization. The hypothesis is that the Th1 cells polarized response
is not induced early in life leaving the body more susceptible to
developing Th2 induced disease (Strachan, 2000). First, Strachan
(1989) mentioned that the hypothesis was proposed to explain
the observation that hay fever and eczema were less common in
children from larger families, which were presumably exposed to
more infectious agents through their siblings, than in children
from small families, especially without siblings. Many bacteria and
viruses derive a Th1-mediated immune response, which down-
regulates Th2 responses. The urban-rural gradient in prevalence
has been demonstrated most strongly in children who grew up in
environments with a wide range of microbial exposures, who are
protected from childhood asthma and atopy (the predisposition
to develop IgE against common environmental allergens) in pro-
portion to their level of exposure to bacterial and fungal microbes
(Ege et al., 2011).
In association with the airway epithelium and underling
mucosa is a specialized population of antigen-presenting cells
(APCs) called DCs (Holgate, 2012). As allergen sensitization, DCs
take up the allergens and present small peptide from them. DCs
express receptors of the innate immune system and process aller-
gens into small peptides and then present them through the major
histocompatibility complexes, MHC class I and MHC class II for
recognition by T cell receptors. In allergic individuals, it is pro-
moted by interaction of the allergen with IgE attached to FcεRI,
the high-afﬁnity receptor for IgE (Sallmann et al., 2011). When
individual is born, there is no DCs in the airway. Damage to and
activation of the respiratory epithelium are the major stimuli that
initiate the ingression of immature DCs from the bone marrow
(McWilliam et al., 1994) and cause the release of C–C chemokines
which direct DCs migration toward the epithelium and under-
lying mucosa (Hammad et al., 2010). GM-CSF, which is released
from epithelial cells and immune cells in the presence of IL-4 and
TNF-α, leads to DCs maturation to a fully competent as APCs.
During initial allergen entering to airways to sensitize, Th2 lym-
phocyte differentiation from naïve T cells requires IL-4 release.
The cellular source of the IL-4 is still unclear. There are some
hypotheses to explain that (Holgate, 2012). Polarization to Th2
cells subtype is also under epigenetic regulation. From the study
with mouse, microRNA-21 has been shown to exert a pivotal role
in setting a balance between Th1 and Th2 responses. It works
through binding the promoter of the gene encoding IL-12 p35
and inhibiting its activation in favor of a Th2 proﬁle. Conversely,
reduced microRNA levels lead DCs to produce more IL-12, and
allergen-stimulated T cells to produce more interferon-γ (IFN-γ)
and less IL-4, enhancing Th1 delayed-type hypersensitivity (Lu
et al., 2011).
DENDRITIC CELL ACTIVATION
As described above, DCs present small peptide from antigens
through MHC class I and II/ T cell receptors. Once sensi-
tized, T cells drive the allergic response in progress through
interactions with DCs (Veres et al., 2011). DCs spread their pro-
cesses into the lumen between airway epithelial cells and can
detect allergen by forming tight junctions, keeping the epithelial
barrier (Blank et al., 2011). In mouse, two distinct DC sub-
sets have been described in accordance with their expression
of the CD11c as myeloid [conventional DCs (cDCs), CD11c+]
or plasmacytoid DCs (pDCs, CD11c−; Lambrecht and Ham-
mad, 2009). Similarly, human DCs are subdivided into CD11c−
pDCs and CD11c+ myeloid DCs. Induced sputum from asth-
matic airways and peripheral blood contain increased numbers
of both pDCs and cDCs, which further increase in number
upon allergen challenge (Dua et al., 2010). Proteolytic activi-
ties of allergens initiate to mature DCs. In a few hours after
contact with allergen, pattern-recognition receptors activation,
such as Toll-like receptors (TLRs) on DCs augments their hom-
ing capacity by upregulating chemokine receptors. It is cDC
subtypes that are predominantly responsible for antigen presen-
tation. Mature DCs shape an immunological synapse with the
allergen-speciﬁc T lymphocytes to initiate a Th response (Hol-
gate, 2012). Whereas some of the Th cells make their way to
the B-cell follicle to facilitate immunoglobulin class switching
from IgM to IgE, others move back to the airway mucosa to
elicit the classical Th2 response through the secretion of the
proallergic cytokines. Pattern-recognition receptors have a cru-
cial adjuvant role in directing allergen sensitization. TLRs are key
components of the innate immune system that mediate recog-
nition and response to pathogen-associated molecular patterns
(PAMPs) in the form of microbial, fungal and viral products and
their ligands, including endotoxin which is recognized by TLR4,
lipoproteins (TLR2 and TLR6), viral double- and single-stranded
RNA (TLR3 and TLR7/8) and bacterial CpG-containing DNA
(TLR9) (Akira et al., 2006). Other pattern recognition receptors
respond to endogenously generated damage-associated molecu-
lar pattern molecules (DAMPs) produced during tissue damage.
Inﬂammatory DCs have been suggested to be necessary and suf-
ﬁcient for the development of Th2 immunity to house dust mite
allergen when the ﬁrst exposure occurs by inhalation. For inhaled
allergens, it is proposed that DCs amplify the Th2 immunity
through basophiles and, in part, inﬂuenced by innate signaling
through TLR4 and C-type lectin signaling on epithelial cells and
DCs (Trompette et al., 2009). A cooperation of airway epithelium
and DCs controls asthma development Th2 activation requires
DCs-mediated antigen-presentation. Then, allergic sensitization
fails to develop in the absence of DCs (Hammad et al., 2010),
while DCs remain inactive in the absence of TLR ligation (Per-
ros et al., 2009). That is, TLRs activation on epithelial cells
enhances DCs motility and antigen sampling through the produc-
tion of Th2-promoting chemokines and cytokines (IL-25, IL-33,
GM-CSF).
VIRAL INFECTION TO PREDISPOSITION
The fact that early-in-life sensitization to multiple allergens car-
ries the greatest risk for developing asthma (Simpson et al., 2010)
brings the question of what factors result in a predisposition to
this phenotype. Although infection with rhinovirus is the major
cause of acute exacerbation, in those genetically at risk of asthma,
rhinovirus-induced wheezing in the ﬁrst three years in the life is
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also the greatest risk factor for developing asthma at 6 years of
age (Jackson et al., 2008). Impaired TLR3-mediated IFN-β and
-λ production by asthmatic epithelial cells would make suscepti-
ble to both viral infection and allergic sensitization (Wark et al.,
2005; Contoli et al., 2006; Bosco et al., 2010; Jartti and Korppi,
2011). Reduced primary IFN production by lower-airway epithe-
lial cells enables some viruses to replicate, leading to cytotoxic cell,
release of inﬂammatory products and enhanced viral shedding.
Such events provide a strong stimulus for recruitment of immature
DCs and their priming for allergen sensitization (McWilliam et al.,
1994, 1996). When asthmatic epithelial cells are received to dam-
age by rhinovirus infection, the cells generate increased amounts
of the pro-Th2 cytokine thymic stromal lympoietin (Uller et al.,
2010), which stimulates DCs and increases allergic inﬂamma-
tion, whereas exogenous IFN-b applied to asthmatic epithelium
exerts anti-Th2 as well as antiviral properties (Cakebread et al.,
2011).
CELLULAR IMMUNITY
Asthma is classically considered Th2 disease, with increased IgE
and eosinophilic inﬂammation caused by increased levels of Th2-
type cytokines. However, this paradigm has been challenged
because of the realization that strategies designed to suppress
Th2 function are not effective for all patients. The clinical phe-
notype of asthma is notoriously heterogeneous. It is shown that
cellular immune process in the asthmatic airways in Figure 2.
Th2 cells activation requires antigen-presentation by DCs. DCs
play a role both in the initiation and maintenance of allergic
airway inﬂammation and asthma, and control many aspects of
the disease, including bronchial hyperresponsiveness and goblet
cell metaplasia, by controlling the recruitment and activation of
Th2 cells (Lambrecht and Hammad, 2009; Schuijs et al., 2013).
Researches in both mouse and human, mentioned the expres-
sion of Th2-type cytokines, such as IL-4, IL-5, and IL-13, in
the allergic lung. Experimental asthma models indicate that these
cytokines, IL-13 in particular, are critical in driving key patho-
logic features of the allergic response. Moreover, Th2 blockade
is very effective in suppressing these features of allergic dis-
ease in mice (Finkelman et al., 2010). The classical asthmatic
phenotype is one of eosinophilia concomitant with high IgE
levels. However, a proportion of patients are not atopic and
do not have eosinophilic inﬂammation. In fact, it is estimated
that as many as 50% of adult patients are encompassed by
this non-atopic, non-eosinophilic, non-IgE-dependent subgroup
(Lloyd and Saglani, 2013). Molecular therapy data support an
overall Th2 association with phenotypes, such that they might
satisfy a deﬁnition of Th2-associated asthma. However, even
these distinctions are too simple, especially when disease sever-
ity is considered. Although children with severe asthma have
eosinophilic inﬂammation, high-dose steroids effectively sup-
press Th2-type cytokines, such as IL-13 and IL-5, but symptoms
remain with persistent eosinophilia (Bossley et al., 2012), thus
raising the importance of identifying other less steroidsensitive,
non-Th2 mediators driving disease. Then, it is apparent that
asthma can no longer be considered simply a Th2-mediated
disease.
FIGURE 2 |T cell immune response in the asthmatic airways. Naïve
T cell is received allergen presentation by DCs. The pathway begins with
the development of Th2 cells and their production of the cytokines IL-4,
IL-5, and IL-13. These cytokines stimulate allergic and eosinophilic
inﬂammation as well as epithelial and smooth-muscle changes that
contribute to asthma pathobiology. Th9 cell can be induced and stimulate
mast cells by IL-9. Naïve T cell is also differentiated to Th1 or Th17
cells depending on the existence of cytokines in the microenvironment.
Th1 cell and Th17 cell stimulate and induce neutrophilic
inﬂammation. EMT, epithelial-mesenchymal-myoﬁbroblast transition;
MMP, matrix metalloproteinase; MBP, major basic protein;
LT, leukotriene.
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FIGURE 3 |T helper cell subsets and cytokine profiles. Th1, Th2 andTh17 cells are a separate lineage of CD4+T cells, distinct from other T cell subsets.
Every speciﬁc T helper cells produce its speciﬁc cytokines (Lazarevic and Glimcher, 2011). T-bet, T-box expressed in T cells; FoxP3, forkhead box P3; ROR,
retinoid-related orphan receptor.
Effector CD4 cells expressing IL-17A, IL-17F were ﬁrst
described in 2005 (Harrington et al., 2005; Park et al., 2005) and
were thought to represent a distinct T-cell lineage that promoted
the ﬁrst revision of the Th1/Th2 paradigm of immunity. Differen-
tiation of naive effector T cells in the presence of IL-6 and TGF-β,
leading to the expression of the transcription factor RORγt, results
in IL-17 expression through the transcription factors Smad 2/3,
signal transducer and activation of transcription (STAT) 3, and
nuclear factor κB. Naïve T cells can differentiate several cell types
and have speciﬁc immune response through the release of cell-
type speciﬁc cytokines (Figure 3). Th17 cells have a role in
regulating both neutrophilic and macrophage inﬂammation in
autoimmune disease, and more recently they have been suggested
to be involved in asthma and corticosteroid insensitivity (Nem-
brini et al., 2009). Conversely, their differentiation is restricted
by both Th1 and Th2 cytokines including IFN-γ, IL-4, and IL-
13 (Park et al., 2005). Speciﬁcally, the induction of CXCL8, a
potent neutrophil chemokine whose expression is elevated in air-
way secretions in severe asthma, has directly implicated Th17 cells
in neutrophilic airway inﬂammation. IL-17A itself, but not IL-17F
or IL-22, enhances the contractile force of ASM. Sensitized mice
lacking the integrin αvβ8 on DCs show reduced activation of this
IL-17A-linked pathway with antigen challenge. This reduction in
smooth muscle contraction in the airways is reversible by IL-17A,
indicating involvement of this cytokine on allergen-induced AHR
by acting directly on ASM (Kudo et al., 2012). Allergic induces
a strong Th17 response in association with airway neutrophilia
and hyperresponsiveness, and this response is abrogated in IL-17F
knockout mice (Yang et al., 2008). However, although a good
case can be made for IL-17A and IL-17F in mouse models of
neutrophilic and corticosteroid-refractory lung responses to aller-
gens, evidence for IL-17 involvement in human asthma is less
robust, despite some emerging genetic evidence and a potential
role for IL-17A and IL-17F in moderate-to-severe disease (Chakir
et al., 2003; Doe et al., 2010). In humans, a subset of Th2 mem-
ory and effector cells has been recognized expressing both GATA3
and RORγt and, as a consequence, producing both Th17 and Th2
cytokines (Cosmi et al., 2010). Studies have reported that the num-
ber of circulating Th17 cells as well as plasma concentrations of
IL-17 and IL-22 increase in proportion to disease severity. In a
bronchial biopsy in asthma vs. normal controls, there was no cor-
relation between IL-17A or IL-17F expression and the extent of
neutrophilia, nor any link to asthma severity (Doe et al., 2010).
The contribution of Th17 cells in human asthma has not been
established enough. It is required to clear association of Th17 cells
and subphenotype in human asthma.
CYTOKINE TARGETS
IL-4/IL-13
The key cytokines involved in Th2-type immunoreaction are those
encoded in the IL-4 gene cluster on chromosome 5q31, contain-
ing the genes encoding IL-3, IL-4, IL-5, IL-9, IL-13, and GM-CSF
(Bowen et al., 2008). The fact that the Th2 pathway is crucial to
asthma pathophysiology has been the driving force for a range
of biologics targeting the speciﬁc cytokines. The signals of Th2-
cell-associated cytokines, IL-4 and IL-13, transmit through the
IL-4Ra/IL-13Ra1 complex. IL-4 promotes B-cell isotype switch-
ing, the upregulation of adhesion molecules, eotaxin production,
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and the development of AHR and goblet cell metaplasia. In animal
model, IL-4 deﬁcient mice were shown to be protected from devel-
oping asthma (Brusselle et al., 1994). IL-13 can have most of these
functions (Wills-Karp et al., 1998;Webb et al., 2000). Furthermore,
those cytokines have the potential to induce TSLP, GM-CSF, and
CCL20 production by the airway epithelium (Reibman et al., 2003;
Kato et al., 2007). Furthermore, IL-13 was shown to have direct
effect to enhance ASM, upregulating RhoA protein which stimu-
lates Rho-kinase inducing calcium sensitivity (Chiba et al., 2009).
Therefore, a good example is the IL-4 and IL-13 pathway for anti
cytokine treatment against asthma.
Given the clear evidence for IL-4 and/or IL-13 in mouse models
of disease were launched and a humanized anti-IL-4 neutralizing
antibody (pascolizumab) was introduced and showed promising
results in human-derived cell lines andmonkeys (Hart et al., 2002).
However, IL-4-speciﬁc antagonists used in clinical trials have failed
(Wenzel et al., 2007). More recently, a human monoclonal anti-IL-
4Ra antibody (AMG317) has been developed but did not show
clinical efﬁcacy (Corren et al., 2010). For IL-13, several neutral-
izing antibodies have been developed, but trials are still in their
infancy. The latter IL-13-antibody (CAT-354) has recently been
shown to be safe for use in humans in a phase I clinical trial
but its real clinical efﬁcacy remains to be proven (Singh et al.,
2010). Attempts to validate importance of IL-13 in human asthma
revealed that only 50% of individuals with asthma had elevated
IL-13 levels in sputum, irrespective of the severity of the disease
(Berry et al., 2004). And Woodruff et al. (2009) have also shown
that only 50% of patients express IL-13-responsive genes in the
airway epithelial cells, and this is linked to a strong Th2 response
in bronchial biopsies, as opposed to in other asthmatics, whose
IL-13-responsive gene expression was almost same level from that
of normal subjects. Th2-high subjects had greater expression of
IL-13 in bronchial biopsies along with greater AHR and higher
serum IgE, blood and airway eosinophilia. It was suggested that
one IL-13 biomarker was periostin (Woodruff et al., 2009). In a
recently published trial, the monoclonal antibody (mAb) to IL-
13, lebrikizumab, when administered to patients with chronic
moderate-to-severe asthma for 12 weeks, signiﬁcantly increased
baseline spirometry (5.5%). This resultwas enhanced in thosewith
elevated serum periostin (high periostin 8.2% vs. low periostin
1.2%; Corren et al., 2011).
IL-5
IL-5 is a key cytokine crucial to eosinophil growth, matura-
tion, activation, and survival whose blockade in various animal
models has a strong effect on acute and more sustained pul-
monary eosinophilia and attendant changes in lung function. It is
mainly produced by Th2-lymphocytes, mast cells and eosinophils.
Interestingly, IL-5 regulates its own receptor expression during
eosinophil ontogeny consisting of an IL-5- speciﬁc receptor α-
chain, and common β-chain. Because of its restriction to the
eosinophil/basophil lineage in humans, IL-5 therapy may atten-
uate key characteristics of allergic airway inﬂammation, such
as airway eosinophilia, airway remodeling, and AHR, without
affecting the function of other immune cells (Triﬁlieff et al.,
2001; Flood-Page et al., 2003; Humbles et al., 2004). It has also
been implicated in the induction of AHR, as IL-5 inhalation by
asthmatic patients induces eosinophil inﬂux and AHR (Leckie
et al., 2000). However, despite markedly reducing both circulating
and sputum eosinophilia, two humanized mAbs, mepolizumab
and reslizumab, when administered to patients with moderate-
to-severe asthma, had no overall effect on any asthma outcome
measures. Nonetheless, the studies of mepolizumab for patients
with severe asthma requiring oral corticosteroids and persistent
sputum eosinophilia showed a good clinical response (Haldar
et al., 2009; Nair et al., 2009), as also found in Churg-Strauss and
other hypereosinophilic syndromes (Abonia and Putnam, 2011).
Similar results have also been obtained with reslizumab (Castro
et al., 2011; Spergel et al., 2012). Efﬁcacy of mepolizumab has also
beendescribed in severe eosinophilic nasal polyposis inproportion
to nasal lavage IL-5 levels (Gevaert et al., 2006). A further devel-
opment of this approach has been the introduction of a highly
active mAb targeting IL-5Rα (benralizumab), which has been
defucosylated to enhance its antibody-dependent cell-mediated
cytotoxicity potential (Kolbeck et al., 2010). The studies demon-
strate that anti-IL-5 therapy is effective in reducing exacerbation
frequency in severe asthma, with highest efﬁcacy in subgroups of
patients where eosinophils have a pathogenic role. A phase 1 study
inmild asthmahas shown a strong dose-related reduction of circu-
lating eosinophils lasting 8–12 weeks after a single injection (Busse
et al., 2010). It seems, however, that for the majority of asthmatic
patients the anti-IL-5 treatment will need to be administered in
combination with other therapies that suppress asthma features
through other mechanisms. Results of clinical trials targeting the
IL5Rα subunit to obtain long-term depletion of eosinophils and
basophils are eagerly awaited.
IL-17/IL-22
The rapid emergence and characterization of the Th17 lineage
(CD4 T cells producing IL-17 family; IL-17A, IL-17F, IL-22)
reﬁnes the existing model and provides a more uniﬁed perspec-
tive of allergic inﬂammation by CD4+ T cell subsets. Interestingly,
some asthmatic individuals, especially those poorly responding to
steroid treatment, show airway inﬁltrations primarily composed
of neutrophils. These cells are probably recruited to the airways by
IL-17-producing cells that also produce IL-4 (Wang et al., 2010a).
In mice, allergic sensitization followed by challenge of the air-
ways induces a strong Th17 response and IL-17 controls bronchial
hyperresponsiveness and airway remodeling, and some of these
effects are mediated directly on bronchial smooth muscle cells
(Pichavant et al., 2008;Wang et al., 2010b; Bellini et al., 2012; Kudo
et al., 2012). Moreover, IL-17 can also induce steroid insensitivity
in bronchial epithelial cells (Zijlstra et al., 2012). IL-22 can also
be produced by Th17 cells. In mouse asthma models, IL-22 seems
to exert a dual role. Indeed, IL-22 blockade in Th2 sensitization
dramatically reduced eosinophil recruitment, Th2 cytokine and
chemokine production, AHR, and mucus production. In contrast,
IL-22 inhibition in allergen challenge induced lung inﬂammation
and increased Th2 cytokine production. On epithelial cells, IL-22
has the potential to induce the production of antimicrobial pep-
tides and to promote epithelial repair as well as suppressing the
production of proinﬂammatory chemokines and cytokines (Pen-
nino et al., 2012). Despite these studies, our knowledge of IL-22 in
asthma pathophysiology is still limited.
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Table 1 | Monoclonal antibodies against IL-17 pathway clinical trials.
mAbs Description Phase Indications
Brodalumab Full human IgG2/anti IL-17RA II Asthma, Ps, PsA, RA
Secukinumab Full human IgG1K/ anti IL-17A III Ps, PsA, RA, AS
II veitis
Ixekizumab Humanized, hinge-modiﬁed IgG4/anti IL-17A III Ps
II RA
I PsA
Ustekinumab Full human IgG1/anti p40 of IL-12/23 III Crohn’s, PsA
II AS, sarcoidosis, cirrhosis
Approved Ps
CNTO 1959 Full human mAb/anti p19 of IL-23 II PsA
MK-3222 Humanized mAb/ anti p19 of IL-23 II Ps
AMG 139 Full human mAb/ anti IL-23 I Crohn’s, Ps
RG4934 Humanized mAb/ anti IL-17A I
NI 1401 Full human IgG1 mAb/ IL-17A/F I
SCH 900117 Humanized mAb/ IL-17A I
Ps: psoriasis; PsA: psoriatic arthritis, RA: rheumatoid arthritis; AS: ankylosing; spondylitis.
IL-17A has been considered as one of most important player
in asthma, however, clinical attempts for anti-IL-17A therapy to
asthma has just begun (Table 1). Any data in anti-IL-17A trials
for asthma are not available so far. Some clinical trials targeted
at IL-17A have conducted and substantiated importance of IL-
17A in autoimmune disorders. Phase II data on secukinumab,
ixekizumab, and brodalumab in psoriasis indicate rapid and pro-
nounced effects on measures of disease activity (Hueber et al.,
2010). Early clinical trials in psoriatic arthritis, rheumatoid arthri-
tis, and ankylosing spondylitis also support the therapeutic utility
of IL-17A inhibition.
In addition, whereas secukinumab and ixekizumab selectively
target andneutralize IL-17A,brodalumabbinds the IL-17RA chain
of the heteromeric IL-17 receptor, which is shared with multiple
members of the IL-17 cytokine family and is therefore expected
to inhibit the biological activity of IL-17A and IL-17F as well as
IL-17C (Ramirez-Carrozzi et al., 2011), IL-17E (IL-25) and poten-
tially other not yet discovered IL-17 family members that utilize
IL-17RA (Papp et al., 2012). Consideringwith these data fromclin-
ical trials for autoimmune disease, this hypothetical advantage for
IL-17A inhibitors against asthma can be expected to have clinical
beneﬁts. We have to wait that data from asthma studies becomes
available.
IL-9
Interleukin-9 produced from CD4+ T cell (Th9) has been iden-
tiﬁed as a subset deﬁnite from the classical Th2 cells, requiring
the transcription factors IRF4, PU1, STAT6, Smad3, and Notch
signaling for development. The cells differentiate in response to
IL-4 and TGF-β and are described to promote T cell proliferation,
IgE and IgG production by B-cells, survival and maturation of
eosinophils, increasing the number of mast cell (Veldhoen et al.,
2008; Staudt et al., 2010; Kearley et al., 2011; Elyaman et al., 2012;
Goswami et al., 2012). Studies in human have also shown that
IL-9 expression increased markedly in response to allergen chal-
lenge (Erpenbeck et al., 2003) and IL-9 is highly expressed and
localized to tissue lymphocytes during intestinal parasite infection
(Faulkner et al., 1998) and to CD3+ cells in bronchial submucosa
and BAL (Shimbara et al., 2000). In studies using IL-9 transgenic
and knockout mice, direct IL-9 instillation into the lungs and
blocking mAbs, it has been shown that IL-9 drives mucus produc-
tion, both by a direct effect on airway epithelia (Bryce, 2011) and
also by interacting with IL-13 (Steenwinckel et al., 2007). Mice
with IL-9 overexpression in lung have increased airway inﬂam-
mation and AHR (Bisgaard et al., 2007; Gern, 2011). IL-9 is also
made by ILC2s and boosts production of IL-5 and IL-13 (Rabi-
novitch et al., 2005). Along with IL-4 and stem cell factor, IL-9 is
also a potent stimulus for mast-cell development (Kearley et al.,
2011). As IL-9 has been implicated in both inﬂammatory and
remodeling components in mouse models of allergic airway dis-
ease, it seems an attractive therapeutic target. Currently, clinical
data on anti-IL-9 therapeutics are modest and larger clinical tri-
als are eagerly awaited to conclude whether this form of therapy
can be used in the treatment of asthma (Shalev et al., 2011). Two
ﬁrst-in-human, open-label dose-escalation trials of a monoclonal
antibody against IL-9, MEDI-528, in normal subjects and subjects
withmild asthmahave been successfully completed, showing some
evidence of efﬁcacy (Parker et al., 2011).
TNF-α
Tumor necrosis factor α, a multifunctional cytokine that exerts
a variety of effects, such as growth promotion, apoptosis,
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angiogenesis, cytotoxicity, inﬂammation, and immunomodula-
tion, has been implicated in several inﬂammatory conditions.
This cytokine is not only produced predominantly by activated
macrophages but also by other immune (lymphocytes, natu-
ral killer cells, mast cells) as well as stromal (endothelial cells,
ﬁbroblasts, microglial cells) cells and presents in increased con-
centrations in bronchoalveolar ﬂuid from the airways of patients
with asthma (Broide et al., 1992). Some studies mentioned a
relationship between TNF-α and severity of asthma.
The rates of death and complications are high among patients
with refractory asthma and account for a disproportionate amount
of the health resource burden attributed to asthma (Serra-Batlles
et al., 1998). The airway abnormality in severe asthma is different
from that in more mild asthma in having a more heteroge-
neous pattern of inﬂammatory response (Wenzel et al., 1999),
with greater involvement of neutrophilic inﬂammation and the
distal lung (Berry et al., 2005) and increased airway remodeling
(Busse et al., 1999). Interest in the role of TNF-α in refractory
asthma has been increased by a study showing increased con-
centrations of TNF-α in BAL from patients with more severe
asthma and by an uncontrolled study showing that treatment
with the recombinant solubleTNF-α receptor etanerceptmarkedly
improved AHR in patients with refractory asthma (Howarth et al.,
2005). On the other hand, targeting TNF-α in severe asthma with
golimumab yields responders and non-responders (Wenzel et al.,
2009). And administration with inﬂiximab for severe asthma also
does responders and non-responders (Taillé et al., 2013). There-
fore, controlled studies have shown controversial results and the
risk-beneﬁt proﬁle of TNF-blocking agents is still debated (Cox,
2009).
The studies suggest that anti-TNF-α agents might improve
the condition of a subgroup of patients severe steroid-dependent
asthma, who have life-threatening exacerbations and complica-
tions of long-term steroid therapy. In the studies, the identiﬁcation
of more neutrophilic asthma that is less dependent upon Th2
mechanisms and, as a consequence, less responsive to corticos-
teroids might help identify a responsive target subpopulation.
Such patients have been shown to have high circulating TNF-α
andCXCL-8 as biomarkers (Silvestri et al., 2006). A transcriptomic
analysis applied to induced sputum has identiﬁed a unique signa-
ture with prominence of TNF-α and nuclear factor-κB pathways
(Baines et al., 2010). This stratiﬁcation of asthma into pathway-
selective phenotypes is likely to be a key driver for future drug
development, as is proving so successful for cancer treatments
(Holgate, 2012).
CONCLUSION
Bronchial asthma is a world-wide common disease and charac-
terized by reversible airﬂow limitation, with non-speciﬁc AHR
related to airway inﬂammation. Airway inﬂammation induces not
only asthmatic symptoms which are the reversible airway obstruc-
tion and ASM contraction but also airway remodeling. Lately,
the information for airway remodeling is increasing, the number
of myoﬁbroblasts increases in the understructure of epithelium,
the proximity of the smooth muscle layer and the lamina retic-
ularis. And it is more understood what EMT is. EMT can play
a important role in airway remodeling. These epithelial and mes-
enchymal cells cause persistence of the inﬂammatory inﬁltrate and
induce histological changes in the airway wall, increasing thick-
ness of the basement membrane, collagen deposition and smooth
muscle hypertrophy andhyperplasia. Subepithelial collagens cause
thickening and increasing density of the basement membrane.
Classically, asthma is considered as Th2 disease, relating to
increased IgE and eosinophilic inﬂammation in the airway. Recent
results have shown that not only Th2, but Th17 and Th9 cells sub-
set also contributed the disease, releasing their speciﬁc cytokines.
These different cytokine give different biological effect. These can
be targeted as an anti-cytokine treatment in asthma and some
monoclonal antibodies against speciﬁc cytokines or their recep-
tors are available. The results of those clinical trials have said that
trials failed to control disease, despite it was clearly conﬁrmed that
those cytokines contributed the disease in animal model studies.
It is required that more information for subphenotype of human
asthma and its mechanism in more detail.
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